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Abstract
Introduction
• 8% of all adults over the age of 20 suffer from depression
– Women are twice as likely to be affected (CDC, 2018)
• Depression is the 6th most costly health condition overall with $71 
billion spent annually (Winerman, 2017)
• Diagnosis is clinical with the use of screening tools such as the 
PHQ-9
• Psychotherapy is the recommended first-line treatment, but 
pharmacotherapy is more commonly used due to availability and 
convenience (DynaMed, 2018)
• Recent research shows alternative therapies, including exercise, 
may be just as beneficial as traditional therapies while avoiding side 
effects and limiting the use of medication
Statement of the Problem
Literature Review Applicability to Clinical Practice
References 
Research Question
Major Depressive Disorder (MDD) is a common disease seen every 
day by primary care providers across the United States. According to 
the Centers for Disease Control and Prevention (CDC, 2018), eight 
percent of all adults over the age of 20 suffer from depression, and a 
study by the American Psychological Association found depressive 
disorders to cost roughly $71 billion annually. Today, psychotherapy is 
the recommended first-line therapy for treating MDD, but 
pharmacotherapy is more commonly used. Alternative forms of therapy 
are also being researched in order to avoid the use of medication while 
adequately treating the symptoms of MDD. For this review, seven 
databases were searched including PubMed, Cochrane Database of 
Systematic Reviews, PsycInfo, Cinahl, DynaMed, ClincalKey, and 
ScienceDirect from September 1 to November 21, 2018. Works chosen 
for review were published after the year 2000 and included randomized 
controlled trials (RCTs), systematic reviews, and meta analyses. This 
review found several benefits of using exercise to treat MDD while 
reducing risks, but exercise alone is not superior in effectiveness to 
psychotherapy or pharmacotherapy. Overall, exercise offers the 
greatest benefit in reducing MDD symptoms when used as an 
augmented therapy to either psychotherapy or pharmacotherapy. 
Limitations of this literature review include lack of studies with longevity 
or large sample sizes. 
Keywords: pathophysiology, exercise, depression, SSRIs, selective 
serotonin reuptake inhibitors, Major Depressive Disorder, MDD 
• With the increasing cost of medications and potential for high risk 
side effects, some providers are recommending alternative 
therapies to SSRIs for adult patients diagnosed with mild MDD in 
hopes of providing an option that is safer and more cost effective 
while providing the same benefit. Further research is needed to 
show if exercise and SSRIs are equal in efficacy in the reduction of 
symptoms associated with mild MDD in adults.
• Pathophysiology of MDD
– Exact pathophysiology remains unknown, but many hypotheses 
exist 
– Two common theories:
• Biogenic monoamine theory: basis for pharmacologic treatment, 
developed after medications unexpectedly increased 
monoamine neurotransmitters in the brain by blocking MAOI or 
reuptake of neurotransmitters such as serotonin (Fekadu, 
Shibeshi & Engidawork, 2016)
• Combined source of pathogenesis: Environmental stress 
combined with genetic factors act on immunologic and 
endocrine responses to cause structural and functional changes 
in the brain leading to dysfunction of neurogenesis and 
neurotransmitters which ultimately causes symptoms of 
depression (Jesulola et al., 2018)
• Exercise in the Treatment of MDD
– SMILE study assigned groups to supervised exercise, home 
exercise, sertraline, or placebo pill (Blumenthal et al., 2007):
• 41% of participants achieved remission based on HAM-D at the 
completion of the study including:
–45% of supervised exercise participants
–40% home exercise
–47% medication
–31% placebo pill
– Cochrane review compared exercise versus control and 
pharmacological treatments (Cooney et al., 2013):
• Exercise was moderately more effective than control
–Resistance or resistance + aerobic exercise at a vigorous 
intensity was the most effective
• No statistical difference between pharmacologic treatment and 
exercise
– Systematic review of RCTs by Danielsson, Noras, Waern, and 
Carlsson (2013): 
• No statistical difference between exercise and antidepressants
• No statistical difference between exercise versus physical 
activity
• Small effect of augmenting exercise to traditional treatment 
versus traditional therapy alone
– RCT by Dunn, Trivedi, Kampert, Clark, and Chambliss (2005): 
• Exercise at a higher energy expenditure of 17.5kcal/kg/week is 
superior to lower energy expenditure
– RCT by Bartholomew, Morrison, and Ciccolo (2005):
• Single episode of exercise compared to 30 minutes of rest 
resulted in no improvement in depressive symptoms, but 
exercise produced an acute change in positive well-being
• SSRIs in the Treatment of MDD
• Depression is one of the most common illnesses seen by primary 
care providers today
• CBT is the recommended first-line treatment, but the convenience of 
pharmacotherapy has appealed to many causing SSRIs to become 
first-line
• SSRIs come with risks, however, and providers should be educated 
on alternative forms of therapy that may be of equal benefit without 
the added risks of medication 
• Benefits of using exercise to treat MDD include minimizing 
medication use, avoiding side effects, reducing cost, improving self-
confidence, aiding in weight loss, and improving overall health
• Research on this topic is becoming very popular but current 
research includes more women than men and lacks longevity
• At this point in the research, exercise is noted to have a moderate 
effect on depression, but after correcting for bias, the effect may 
only be small (Cooney et al., 2013)
• Future research should be completed to correct for weaknesses 
noted throughout the studies
• Overall, exercise at this point cannot be reported as a superior 
therapy over traditional options such as pharmacotherapy or 
psychotherapy, but it can be recommended as a beneficial 
augmented therapy in addition to traditional treatments for all 
patients with MDD
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Discussion
• Exercise in the Treatment of MDD
– Exercise alone is effective at improving depressive symptoms 
(Dunn et al., 2005 & Bartholomew et al., 2005)
– Higher dose and intensity of exercise produced greater effects 
(Dunn et al., 2005)
• Exercising at energy expenditure of 17 kcal/kg/wk 3 or more 
times per week is just as effective as traditional therapy (Dunn 
et al., 2005)
– Exercise also improved positive well-being for a short period of 
time (Bartholomew et al., 2005)
– Exercise provided benefits over medication or CBT including: 
reduction of risk of mortality from diseases such as cardiovascular 
disease and obesity (Dunn et al., 2005)
– Weaknesses of the current research include:
• Lack of blind due to nature of exercise as treatment
• Small sample sizes
• Studies lack longevity
• SSRIs in the Treatment of MDD
– SSRIs effective at treating mild MDD (Garnock-Jones & 
McCormack, 2010, Li et al., 2017, & Arrol et al., 2009)
• SSRIs more effective than placebo (Garnock-Jones & 
McCormack, 2010 & Arroll et al., 2009)
• SSRIs more effective at preventing relapse than placebo 
(Garnock-Jones and McCormack, 2010)
– Relatively safe with only mild to moderate intensity side effect 
noted with increased incidence at higher dosages (Garnock-Jones 
& McCormack, 2010
– Weaknesses of the current research include:
• Small sample sizes
• Studies lack longevity
• No specific recommendations regarding dose and duration
• Exercise Compared to SSRIs in the Treatment of MDD
– Results varied based on the study: 
• Blumenthal et al. (2007) found exercise to be comparable to 
antidepressant medication in achieving remission
• Cooney et al. (2013) found exercise to be less effective than 
antidepressants or psychological therapy and only moderately 
more effective than control
• Danielsson et al. (2013) concluded exercise is beneficial as an 
augmentation to medication
– Weaknesses of the current research include:
• Studies lack longevity
• Small sample sizes
Literature Review
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Figure 2: Adverse effects associated with escitalopram  
– Review on escitalopram: more effective than placebo at 
decreasing antidepressant effects and preventing relapse
• Side effects mostly mild to moderate in severity and generally 
well-tolerated (Garnock-Jones & McCormack, 2010)
– Meta-analysis pooled studies on effectiveness of escitalopram: 
significantly reduced depressive symptoms
• Response rate 76.9% and remission rate 64%
• Side effects mild to moderate in severity, considered generally 
safe (Li, Shen, Lou, & Li, 2017)
– Cochrane review: benefits associated with SSRIs significantly 
greater than that of placebo (Arroll et al., 2009)
• In adult patients diagnosed with mild MDD in a primary care setting, 
does treating with exercise as a stand-alone therapy compared to 
treating with SSRIs adequately improve symptoms while minimizing 
side effects?
